Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US. 

Clinical Trials

Health Care

Health Services

Life Sciences

Research

Sarah Cannon Research Institute

Dee Anna Smith

Anne Hoang

Caroline Hudson

Michelyn Smith

Philip Bunting

David R. Spigel

Vivek Subbiah M.D.

Andrew Kennedy

Marcy Vallone

Jennifer Cole

David Adler

Chandra King

Shaolin Paul

Amber Woodward-Smith

The Leadership Team at Sarah Cannon Research Institute (SCRI) is responsible for setting strategic direction, overseeing research operations, and ensuring financial health and sustainable growth of the organization. Comprised of top executives and key leaders, the team works to enhance clinical trial access and availability, foster innovative drug development, and maintain SCRI’s position as a leader in oncology research. They coordinate efforts across various departments to align with the institute's mission of advancing therapies and improving patient outcomes.

Leadership Team

Clinical Research and Data Management

Financial Analysis and Reporting

Leadership Team

About

Team members

Other teams at Sarah Cannon Research Institute

Clinical Research and Data Management

Financial Analysis and Reporting

Leadership Team